Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A method classifying biologics for formulary decision making.

Michael S Broder1, Debi Reissman

  • 1Partnership Health Analytic Research, LLC, Los Angeles , California 90025, USA. mbroder@pharllc.com

Managed Care Interface
|May 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health outcomes and survival among patients with severe hypertriglyceridemia after acute pancreatitis.

Journal of clinical lipidology·2025
Same author

Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Hematology (Amsterdam, Netherlands)·2025
Same author

Adherence, duration and healthcare costs in a real-world population of patients with acromegaly.

Journal of comparative effectiveness research·2025
Same author

Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotide.

Journal of comparative effectiveness research·2025
Same author

Healthcare utilization and costs among patients with acromegaly in the United States.

Journal of comparative effectiveness research·2025
Same author

Clinical and economic burden among older adults with acromegaly in the United States.

Journal of comparative effectiveness research·2025
Same journal

Changes in hospital readmissions for diabetes-related conditions. Differences by payer.

Managed care interface·2008
Same journal

Heart disease and managed care.

Managed care interface·2008
Same journal

A conversation with James K. Min, MD.

Managed care interface·2008
Same journal

Acute coronary syndromes.

Managed care interface·2008
Same journal

Improving outcomes in cardiovascular disease.

Managed care interface·2008
Same journal

The effect for oncology of the national coverage determination for erythropoiesis-stimulating agents.

Managed care interface·2008
See all related articles

Pharmacy and Therapeutics Committees face challenges classifying biologic agents for formularies. A suggested method, using psoriasis biologics as examples, aids in appropriate classification.

Area of Science:

  • Pharmacology
  • Drug Development
  • Therapeutics

Background:

  • Pharmacy and Therapeutics Committees require standardized methods for evaluating new biologic agents.
  • Biologic agents present unique classification challenges due to variations in mechanism of action, delivery, and dosing.
  • Existing classification systems may not adequately address the complexities of biologic agents.

Purpose of the Study:

  • To propose a method for classifying biologic agents within pharmacy formularies.
  • To address the challenges in categorizing biologics with similar indications but different characteristics.
  • To provide a practical framework for evaluating biologic agents.

Main Methods:

  • A classification method is suggested for biologic agents.

Related Experiment Videos

  • The method is illustrated using biologic agents for psoriasis treatment.
  • Examples include alefacept, efalizumab, etanercept, and infliximab.

    • Main Results:

    • The study highlights the importance of considering mechanism of action, delivery, and dosing for classification.
    • A systematic approach can help overcome classification hurdles for biologics.
    • The proposed method offers a structured way to evaluate these complex agents.

    Conclusions:

    • A clear classification strategy is essential for the effective formulary incorporation of biologic agents.
    • The suggested method provides a valuable tool for Pharmacy and Therapeutics Committees.
    • Standardized classification facilitates appropriate selection and use of biologics in patient care.